Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + tetrahydrocannabinol (Ontario Brain Institute)
- Development stage
- Unknown
- Lead developer
- Ontario Brain Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a specific combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) in a 16:1 ratio, currently being evaluated in the CERES clinical trial. Developed under the Epilepsy Research Program of the Ontario Brain Institute, it is intended as an adjunctive therapy for adults with drug-resistant epilepsy and frequent convulsive seizures. The formulation leverages the synergistic effects of phytocannabinoids; CBD is thought to reduce neuronal hyperexcitability by modulating calcium signaling through GPR55 and TRPV1 channels, while THC acts as an agonist at CB1 and CB2 receptors within the endocannabinoid system. The therapy is administered orally and titrated based on CBD content to achieve optimal seizure control.
- Other names
- CBD+THCCBD+THC (16:1)Medical CannabisCBD:THC
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR1 (Cannabinoid receptor 1)ENT1 (Solute carrier family 29 member 1)GPR55 (G protein-coupled receptor 55)
Beyond the preview
Go deeper on cannabidiol + tetrahydrocannabinol (Ontario Brain Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + tetrahydrocannabinol (Ontario Brain Institute).